Now showing items 1-3 of 3

    • Mass spectrometry strategies to understand treatment effects and heterogeneity in soft tissue sarcomas 

      Huang P; Chadha, M; Huang, P (Institute of Cancer Research (University Of London), 2024-07-25)
      Soft Tissue sarcoma are rare and heterogenous mesenchymal malignancies. Optimal disease management in STS is surgical excision as the primary treatment modality. Despite negative surgical margins, ~50% of patients relapse. ...
    • Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas. 

      Chadha, M; Huang, PH (SPRINGER, 2022-02-16)
      Advances in proteomic and metabolomic technologies have accelerated our understanding of multiple aspects of cancer biology across distinct tumour types. Here we review the current state-of-the-art in the use of proteomics ...
    • The proteomic landscape of soft tissue sarcomas. 

      Burns, J; Wilding, CP; Krasny, L; Zhu, X; Chadha, M; et al. (NATURE PORTFOLIO, 2023-06-29)
      Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological ...